San L, et al. - The efficacy and safety of inhaled loxapine vs intramuscular (IM) antipsychotic aripiprazole were comparatively analyzed in acutely agitated patients with schizophrenia or bipolar I disorder. This study was performed among patients (aged 18–65 years) diagnosed with schizophrenia or bipolar I disorder experiencing acute agitation (Clinical Global Impression [CGI]-Severity score ≥ 4) while hospitalized or attending an emergency room in 23 centres in the Czech Republic, Germany, Spain, and Russia. As per the data, the between-treatment difference in median time to CGI-Improvement response was 10 min in favour of inhaled loxapine vs 60 min with IM aripiprazole. The variation was prominent at 10 min. No safety issues were reported. Findings demonstrated that inhaled loxapine reduced agitation faster than IM aripiprazole. Thus, it proved to be useful as a first-line option for managing acute agitation in patients with schizophrenia or bipolar disorder.